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Relaxin-1–deficient mice develop an age-related progression of
renal fibrosis.
Background. Relaxin (RLX) is a peptide hormone that stim-
ulates the breakdown of collagen in preparation for parturition
and when administered to various models of induced fibrosis.
However, its significance in the aging kidney is yet to be es-
tablished. In this study, we compared structural and functional
changes in the kidney of aging relaxin-1 (RLX−/−) deficient
mice and normal (RLX+/+) mice.
Methods. The kidney cortex and medulla of male and female
RLX+/+ and RLX−/− mice at various ages were analyzed for
collagen content, concentration, and types. Histologic analysis,
reverse transcription-polymerase chain reaction (RT-PCR) of
relaxin and relaxin receptor mRNA expression, receptor au-
toradiography, glomerular isolation/analysis, and serum/urine
analysis were also employed. Relaxin treatment of RLX−/−
mice was used to confirm the antifibrotic effects of the peptide.
Results. We demonstrate an age-related progression of renal
fibrosis in male, but not female, RLX−/− mice with significantly
(P < 0.05) increased tissue dry weight, collagen (type I) con-
tent and concentration. The increased collagen expression in
the kidney was associated with increased glomerular matrix and
to a lesser extent, interstitial fibrosis in RLX−/− mice, which
also had significantly increased serum creatinine (P < 0.05) and
urinary protein (P < 0.05). Treatment of RLX−/− mice with
relaxin in established stages of renal fibrosis resulted in the re-
versal of collagen deposition.
Conclusion. This study supports the concept that relaxin may
provide a means to regulate excessive collagen deposition dur-
ing kidney development and in diseased states characterized by
renal fibrosis.
Progressive renal disease is characterized by glomeru-
losclerosis [1] and tubulointerstitial fibrosis [2, 3], which
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results in the formation of scar tissue and kidney dysfunc-
tion. At the onset of renal fibrosis there is activation of
extracellular matrix (ECM)–producing fibroblasts, which
differentiate and acquire features of smooth muscle [4].
Differentiated fibroblasts (myofibroblasts) contribute to
the process of scarring and cause hyperproliferation, in-
creased production of several ECM proteins [5], partic-
ularly collagen and reorganization of the ECM. While a
number of therapies have been extensively used in pro-
gressive renal disease [6, 7], most have been limited or
ineffective in reversing the connective tissue deposition
(fibrosis), while others inhibit several mechanisms and
are nonspecific, emphasizing the need for novel antifi-
brotic therapies.
Relaxin (RLX) is a small dimeric peptide hormone
with known antifibrotic properties. While relaxin is pri-
marily produced from the pregnant ovary and prostate of
mammals and has several functions that are generally as-
sociated with female reproductive tract physiology [8], its
ability to inhibit excessive collagen accumulation in var-
ious cell culture and animal models of fibrosis, has been
extensively studied [9–13]. Relaxin acts directly on trans-
forming growth factor-b (TGF-b)–stimulated human der-
mal fibroblasts [9] and lung fibroblasts [10] to promote
the decrease of types I and III collagen synthesis and de-
position. In addition, relaxin has been used to decrease
collagen accumulation in several rodent models of fibro-
sis [10, 11], including a bromoethylamine-induced model
of chronic papillary necrosis [12] and two models of re-
nal injury, caused by mass reduction [13]. These findings
demonstrated that relaxin possessed antifibrotic proper-
ties in the kidney.
Mice have two relaxin genes, known as relaxin-1 [14]
and relaxin-3 [15]. Relaxin-1 is the mouse equivalent of
human-2 relaxin [14] and is the major stored and circu-
lating form of relaxin in the mouse, while relaxin-3 is the
mouse equivalent of the recently discovered human-3 re-
laxin [15]. To aid our understanding of the physiologic
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significance of relaxin-1, our group used gene targeting
to establish a relaxin-1 gene knockout mouse, which lacks
relaxin-1 protein [16]. Our subsequent findings demon-
strated that relaxin-1–deficient mice had poor mammary
gland, nipple, and female reproductive tract development
during late pregnancy due to an increased collagen con-
centration in these tissues [16, 17]. Furthermore, relaxin-
1–deficient mice underwent an age-related progression of
fibrosis in the male reproductive tract [18], lung [19], and
heart [20], confirming that relaxin-1 was a naturally occur-
ring regulator of collagen turnover during development
and pregnancy. However, the significance of relaxin-1 de-
ficiency on kidney phenotypes of these mice is yet to be
established.
The kidney has traditionally not been considered a
source or target tissue of relaxin. However, recent stud-
ies have demonstrated relaxin mRNA expression in the
mouse kidney [15], while relaxin receptor (LGR7) and
relaxin-like factor/insulin-3 receptor (LGR8) gene tran-
scripts were identified in the human kidney [21]. These
findings suggest that the kidney may not only serve as a
target for relaxin activity through its actions on LGR7,
but may act as a source of local relaxin production in
mammals. In the present study, we used relaxin-1 gene
knockout mice to examine the long-term effects of relaxin
deprivation on the structure and function of the kidney
with the specific aim of determining whether the lack of
relaxin affects renal collagen deposition. We also investi-
gated the effects of relaxin treatment in relaxin null mice
with established renal fibrosis.
METHODS
Reagents
Recombinant human relaxin (rH2) was generously
provided by the Connetics Corporation (Palo Alto, CA,
USA) and is bioactive in mice [22].
Animals
All male and female relaxin wild-type (RLX+/+),
relaxin heterezygous (RLX+/−), and relaxin knockout
(RLX−/−) mice used in this study were generated from
RLX+/− (C57Blk6Jx129SV) parents [16]. The animals
were housed in a controlled environment and maintained
on a 14-hour light, 10-hour dark schedule with access
to rodent lab chow (Barastock Stockfeeds, Pakenham,
Victoria, Australia) and water. These experiments were
approved by the Howard Florey Institute’s Animal Ex-
perimental Ethics Committee, which adheres to the
Australian Code of Practice for the care and use of labo-
ratory animals for scientific purposes.
Tissue collection
RLX+/+ and RLX−/− male mice were obtained at 1
month, 6 months, and 12 months of age, while RLX+/+
and RLX−/− female mice were obtained at 1 month
and 12 months of age. Additional female mice (including
RLX+/− mice) were also obtained at 19 months of age
(N = 6 to 8 mice per genotype and gender). All mice were
weighed, before being euthanized for blood and tissue
collection. Both kidneys were collected from each animal
and individual tissues were immediately weighed (wet
weight), before being separated into cortex and medulla.
Tissues were then either stored at −80◦C for hydroxypro-
line analysis and RNA analysis or fixed in 10% formalin
for histologic analysis. For hydroxyproline analysis, sep-
arated cortex and medulla tissue were lyophilized to dry
weight. An additional set of 9-month-old male RLX+/+
and RLX−/− mice (N = 12 to 14 per genotype) were
used for other analyses (determination of collagen types,
glomerular isolation and analysis, autoradiography of re-
laxin receptor binding, serum/urine analysis) as detailed
below.
Hydroxyproline analysis of kidney tissues
The separated cortex and medulla from RLX+/+ and
RLX−/− male and female mice, respectively, from the
different age groups were hydrolyzed with 6 mol/L hy-
drochloric acid and treated as described previously [23].
Hydroxyproline values were then converted to collagen
content by multiplying by a factor of 6.94 [24], while colla-
gen concentration was calculated by dividing the collagen
content by the tissue dry weight.
Determination of collagen types in the kidney
The cortex and medulla of 9-month-old RLX+/+ and
RLX−/− male mice (N = 4 per genotype) were sepa-
rated and finely diced in the presence of liquid nitro-
gen, and the newly synthesized and newly cross-linked
collagen was extracted with 0.5 mol/L acetic acid for
24 hours at 4◦C [25]. Samples were centrifuged at 13,000
rpm for 30 minutes and the acetic acid supernatant (con-
taining the soluble collagen) discarded, while the remain-
ing pellet, containing the maturely cross-linked matrix
collagens were freeze-dried, weighed, and subjected to
limited pepsin digestion (enzyme:subtrate ratio, 1:10) for
24 hours at 4◦C [23]. The pepsin-digested (collagen) su-
pernatants were collected after centrifugation (as above),
freeze-dried, and dissolved in sample loading buffer, as
used before [23].
The collagen chains were analyzed on 5% (wt/vol)
acrylamide gels with a stacking gel of 3.5% (wt/vol)
acrylamide. Interrupted electrophoresis with delayed re-
duction of the type III collagen disulphide bonds was
used to separate the a1(III) chains from the a1(I) col-
lagen chains [26]. The gels were stained overnight at 4◦C
with 0.1% (wt/vol) Coomassie brilliant blue R-250 and
destained as described previously [23].
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Histology of kidney tissues
Fixed kidney tissues from 9-month-old male RLX+/+
and RLX−/− mice (N = 4 to 6 per genotype) were
washed in 70% ethanol before being processed, paraf-
fin embedded, and cut (4 lm sections) using an AO
Spencer 820 microtome. Serial sections from each tis-
sue were stained with hematoxylin and eosin (H&E) to
observe tissue structure/organization and for collagen,
with the Masson trichrome stain. The stained slides were
viewed using a DMRB/E microscope (Leica Microsys-
tems, Gladesville, NSW, Australia), the images captured
using a reverse transcription (RT) slider SPOT digital
camera (Diagnostic Instruments, Sterling Heights, MI,
USA) and stored for retrieval and analysis. Several tissue
sections were screened with each stain and a representa-
tive slide chosen for figure presentation.
Morphometric evaluation of glomerular pathology
Point counting methodologies were used to quantify
glomerular matrix and cells in Masson trichrome–stained
sections. The technique is based on the principle that
points distributed in an independent way onto a given
tissue will hit different tissue compartments according to
the relative extent of each compartment.
Sections were examined using a 20× objective lens
combined with an eye piece graticule with ten equidistant
intersecting lines, or points. For the purposes of analy-
sis, the glomerulus was defined as matrix, cells, capillary
loops, and space surrounding glomerular segments. The
relative portion occupied by solid material (cells and ma-
trix) was calculated from the number of points falling
on solid material, divided by the total number of points
falling on each glomerulus. Results from approximately
15 glomeruli, from each tissue section (per mouse) were
expressed as the percentage fractional area (%FA). Sec-
tions from four RLX+/+ mice and six RLX−/− mice
were used for evaluation.
RT-polymerase chain reaction (PCR) analysis of relaxin
and relaxin receptor expression in the kidney
For RNA extraction, the kidney cortex and medulla
from 1-month-old and 9-month-old RLX+/+ and
RLX−/− male mice (N = 2 per age group and genotype)
were treated as described elsewhere [19].
RT-PCR was used to determine relaxin-1, relaxin-3,
and LGR7 gene expression in the cortex and medulla
of 1-month-old and 9-month-old male RLX+/+ and
RLX−/− mice. Fifty microliter reactions containing
100 ng of primers and 0.5 to 1 lg of the cDNA template
were used for all PCR reactions. All primers used were
designed to span intron-exon junctions and hence control
for genomic DNA contamination. Tissues were screened
for mouse relaxin-1 and relaxin-3 mRNA expression us-
ing primers previously described [15]. Tissues were also
screened for mouse LGR7 expression using previously
published primer sequences [18]. The LGR7 primers used
in these studies were kindly provided by Mr. Daniel Scott
and Dr. Ross Bathgate (Howard Florey Institute).
For relaxin-1 and relaxin-3 expression, PCR was
performed as described previously [14], while touch-
down PCR was used to detect LGR7 expression [18].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used in separate PCR reactions to control for quality
and equivalent loading of the cDNA. Aliquots of the PCR
products were electrophoresed in 2% (wt/vol) agarose
gels, stained with ethidium bromide, and photographed.
PCR products were excised and sequenced for confirma-
tion as described before [19].
Autoradiography of relaxin receptor expression
in the kidney
Kidney tissue from 1-month-old and 9-month-old
RLX+/+ and RLX−/− mice was dissected, slowly frozen
in liquid nitrogen, and stored at −70◦C. Sections (10 lm)
were cut in a cryostat at −20◦C and collected on pre-
cleaned slides subbed with poly-l-lysine (0.01% solu-
tion). Rat brain sections were included as a positive
control. Slide-mounted sections were placed in a moist
chamber (25◦C) and preincubated in HEPES buffer
(25 mmol/L HEPES and 300 mmol/L KCL, pH
7.2) containing phenylmethylsulphonylflouride (PMSF)
(1 lmol/L) for 30 minutes. Slides were incubated with
∼100 pmol/L [33P]-human gene 2 (H2Rlx) (B33) relaxin
for 90 minutes [27]; B33 being the full form of H2 re-
laxin, containing a B-chain of 33 amino acids. Nonspecific
binding was defined with H2Rlx (1 lmol/L). Slides were
washed twice (10 minutes) in buffer, rinsed in distilled
water, air-dried, and apposed onto film for 2 weeks. The
film was developed in Kodak D-19 developer (5 minutes),
Kodak stop solution (1 minute), Kodak fix solution (10
minutes), and gently rinsed in running water (15 minutes).
Images were analyzed with ImageQuaNTTM (version 4.1;
Molecular Dynamics, Sunnyvale, CA, USA).
Isolation and analysis of glomeruli from the kidney
To determine if relaxin deficiency caused changes
in protein and collagen expression in glomeruli, the
glomeruli from 9-month-old RLX+/+ (N = 6) and
RLX−/− (N = 8) mouse kidneys were isolated as de-
scribed before [28], but with some modification. Briefly,
each anesthetized mouse was perfused with 1.4 − 108
Dynabeads (M-280 tosylactivated with 2.8 l diameter)
(Dynal Pty, Ltd., Oslo, Norway) (kindly provided by Dr.
Siew Yeen Chai, Howard Florey Institute) in 40 mL of
phosphate-buffered saline (PBS). The kidneys were re-
moved from each animal and the renal cortex separated
from the rest of the tissue, before the cortex was diced
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Table 1. Total kidney wet weights of aging male and female RLX+/+ and RLX−/− mice
Male RLX+/+ Male RLX−/− Female RLX+/+ Female RLX−/−
Mean ± SE Mean ± SE Mean ± SE Mean ± SE
(number) (number) (number) (number)
1 month of age 0.17 ± 0.002 g (6) 0.18 ± 0.1 g (6) 0.17 ± 0.01 g (8) 0.16 ± 0.01 g (8)
6 months of age 0.25 ± 0.01 g (10) 0.30 ± 0.01 g (10)a — —
12 months of age 0.28 ± 0.01 g (20) 0.32 ± 0.01 g (16)b 0.18 ± 0.01 g (10) 0.20 ± 0.01 g (10)
19 months of age — — 0.25 ± 0.01 g (8) 0.28 ± 0.01 g (10)b
aP < 0.01; bP < 0.05, when compared with corresponding values from gender-matched and age-matched RLX+/+ mice.
into fine pieces. Diced cortical tissue was collagenase-
treated, filtered, and washed as previously described [28].
The glomeruli, containing Dynabeads, were finally gath-
ered with a magnetic particle concentrator (MPC) and
washed, before being stored in Hank’s balanced salt so-
lution (HBSS) (500 lL) and observed under a micro-
scope. Equal aliquots of each glomeruli sample were used
for protein determination and hydroxyproline (collagen)
determination.
For total protein determination, 50 lL aliquots of
samples containing glomeruli (in HBSS) were analyzed
with the Bio-Rad (Richmond, CA, USA) dye-based
protein assay, as described by the manufacturer. The
absorbance of each sample was read in a Beckman
DU-64 spectrophotometer (Beckman-Coulter Pty Ltd.,
Sydney, NSW, Australia) at a wavelength of 595 nm. The
remainder of each sample was hydrolyzed with 6 mol/L
hydrochloric acid and analyzed for hydroxyproline (col-
lagen) content, as described above.
Serum and urine analysis
To determine the functional consequences of relaxin
deficiency on the kidney, serum was isolated from the
blood of 9- to 12-month-old male RLX+/+ (N = 4) and
RLX−/− (N = 7) mice and analyzed for creatinine in
a Beckman Synchron CX-5 Clinical System (Fullerton,
CA, USA). Nine-month-old male RLX+/+ (N = 6) and
RLX−/− (N = 6) mice were maintained in metabolic
cages for a 24-hour period to collect urine for determi-
nation of urinary protein (using the Beckman Synchron
System).
Human recombinant relaxin treatment
of relaxin-deficient mice
Twelve-month-old male RLX−/− mice (N = 13)
were anesthetized and subjected to subcutaneous im-
plantation of osmotic minipumps (model 2002) (Alza,
Cupertino, CA, USA) as described previously [19]. The
osmotic minipumps were loaded with either a 10 mmol/L
citrate buffer, pH 5.0 (vehicle; N = 6) or 0.5 mg/kg/day
rH2 (in citrate buffer; N = 7), which were maintained for
14 days. The dose of rH2 added was previously shown
to produce circulating levels of 20 to 40 ng/mL after
14 days of treatment and successfully treat pulmonary fi-
brosis in 9-month-old and 12-month-old, male RLX−/−
mice [19]. After 14 days, the animals were euthanized,
blood withdrawn by cardiac puncture, kidneys removed
and separated into cortex and medulla for hydroxypro-
line analysis, or placed in 10% formalin for histologic
analysis (as described above). Serum was isolated from
blood of rH2-treated RLX−/− mice (N = 6) and ana-
lyzed for creatinine.
Statistical analysis
The results were analyzed using a one-way analysis of
variance (ANOVA), using the Newman-Keuls test for
multiple comparisons between groups. All data in this
paper are presented as the mean ± SEM, with P < 0.05
described as statistically significant.
RESULTS
The effects of relaxin deficiency on kidney weight,
collagen content, and types
A significant increase (15% to 20%, P < 0.05) in kidney
wet weight was measured from 6 months to 12 months of
age in male RLX−/− mice, compared with age-matched
tissue weights from male RLX+/+ mice (Table 1). No
significant differences between kidney weights of fe-
male RLX+/+ and RLX−/− mice were measured from
1 month to 12 months of age. However, after 19 months
of age, the kidney weights of female RLX−/− mice
were significantly heavier (12% to 15%, P < 0.05) than
age-matched tissues from RLX+/+ and RLX+/− mice
(Table 1).
Figure 1A shows the total dry weight of the cortex (C)
and medulla (M) of aging, normal, and relaxin-deficient
mice. A significant increase in dry weight of the cortex
(32%, P < 0.05) and medulla (15%, P < 0.05) was mea-
sured in male RLX−/− mice at 6 months of age, com-
pared to age-matched tissue weights from male RLX+/+
mice. The increased kidney dry weight of RLX−/− an-
imals was only sustained in the cortex (41% increase,
P < 0.01) of 12-month-old mice (Fig. 1A), which cor-
related with a 20% increase (P < 0.05) in kidney
weight/body weight in RLX−/− mice, as compared to the
same ratio in RLX+/+ mice. In female animals, no sig-
nificant differences in dry weight were measured in the
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Fig. 1. Effects of relaxin deficiency on kidney dry weight (A), collagen content (B), and collagen types (C) in aging mice. The dry weight of the
separated kidney cortex (C) and medulla (M) of male RLX+/+ and RLX−/− mice (from 1 month to 12 months of age) and female mice (from
1month to 19 months of age) was measured, along with the total collagen content from the same tissues at each age group. Total collagen content
was derived from the sum of collagen in the cortex and medulla. The numbers in parenthesis represent number of samples. ∗P < 0.05 and #P < 0.01,
when compared with corresponding values from age-matched RLX+/+ mice. The pepsin-digested collagen, which shows the maturely cross-linked
insoluble collagen types was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), using delayed reduction of the
disulfide bonds with 10% b-mercaptoethanol. The samples consist of a type I/III collagen standard from human dermis and the collagen from two
individual pepsin digests from the cortex and medulla of RLX+/+ and RLX−/− mice, respectively. Four RLX+/+ and four RLX−/− mouse cortex
and medulla extracts were analyzed by SDS-PAGE and gave identical results.
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corresponding tissues of RLX+/+ and RLX−/− mice,
at either 1 month or 12-months of age. As with the wet
weight measurements (Table 1), only after 19 months
of age, did we measure significant increases in cortex
(45%, P < 0.01) and medulla (11%, P < 0.05) dry
weight of female RLX−/− mice, compared to com-
bined age-matched tissues from RLX+/+ and RLX+/−
mice (Fig. 1A). Previous studies have shown that tis-
sues from RLX+/− mice are similar in weight to those
obtained from RLX+/+ mice (when derived from the
C57Blk6Jx129SV strain) [16, 17, 19].
Similar to the pattern of dry weight, a significant eleva-
tion in total collagen content (25.5%, P < 0.05) was mea-
sured by marked increases in cortical (49.5%, P < 0.01)
and medulla (15%, P < 0.05) collagen in 6-month-old
male RLX−/− male mice, compared to measurements
from age-matched RLX+/+ mice (Fig. 1B). A substantial
increment in collagen content was measured in 12-month-
old RLX−/− male mice, in the cortex (80.3%, P < 0.01)
and medulla (33.4%, P < 0.05), resulting in a 47.2%
(P < 0.05) increase in total collagen (Fig. 1B), compared
to values obtained from age-matched RLX+/+ mice. The
progressive increase in kidney collagen content of male
RLX−/− mice corresponded to a significant increase in
collagen concentration (collagen content as a percentage
of the dry weight tissue) by 12 months of age (cortex
21.3%, P < 0.05; medulla 29.8%, P < 0.05). In female
mice, a progressive increase in cortex, medulla, and to-
tal collagen content were measured with age. However,
there were no significant differences in collagen content
between corresponding tissues of RLX+/+ and RLX−/−
female mice, at either age group (1 month, 12 months, and
19 months) studied (Fig. 1B).
Type I collagen was the predominant form of mature
collagen in both the cortex and medulla of 9-month-old
male RLX+/+ and RLX−/− mice, as identified by the
a1(I) and a2(I) subunits (Fig. 1C). A marked increase
in type I collagen monomers (a1(I) and a2(I) subunits),
type I collagen dimers (b11:dimers of two a1(I) subunits;
b12: dimers of a1(I) and a2(I) monomers) and collagen
trimers (c) were observed in renal extracts of RLX−/−
male mice, compared to collagen I levels in RLX+/+ tis-
sue extracts. Trace amounts of type III collagen [a1(III)]
subunits were also detected in cortex and medulla ex-
tracts from RLX−/− male mice, but not from RLX+/+
mouse tissues (Fig. 1C), suggesting that kidney extracts
of RLX−/− mice were also associated with a small in-
crease in type III collagen. Types IV and V collagen were
not examined in either tissue by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).
The effects of relaxin deficiency on kidney histology
Histologically, whole kidney tissue sections from
RLX−/− mice (Fig. 2B) were larger and contained
larger/thickened cortices, than tissue sections from
RLX+/+ mice (Fig. 2A). These findings were consis-
tent with the larger kidney weights from RLX−/− mice
(Table 1). Little ECM (and collagen) was observed in the
interstitial space (Fig. 2C) and within glomeruli (Fig. 2E)
of kidneys from male RLX+/+ mice. However, kidney
tissues from RLX−/− mice were associated with fo-
cal increases in interstitial matrix (collagen) deposition
(Fig. 2D) and a significant (P < 0.02), diffuse increase in
the fractional area of glomerular matrix (RLX+/+ 42.5 ±
4.2%, N = 4; RLX−/− 64.1 ± 5%, N = 6) (Fig. 2F).
Analysis of relaxin and relaxin receptor mRNA
expression in the kidney
Relaxin-1 mRNA expression was only detected in
RLX+/+ mouse tissues, in the kidney cortex and medulla
of immature (1 month) and adult (9 months) animals,
as determined by RT-PCR (Fig. 3). Relaxin-3 mRNA,
however, was detected in both the cortex and medulla
of RLX+/+ and RLX−/− mice (Fig. 3). LGR7 gene
transcripts were inconsistently identified from 3 out of
16 cDNA samples (from immature and adult RLX+/+
mouse tissues only) and required 40 cycles of amplifica-
tion to be detected (Fig. 3).
Autoradiography was performed on kidney sections
from 1-month-old and 9-month-old male RLX+/+ and
RLX −/− age-matched mice, using [33P] human gene 2
(B33) relaxin. None of the kidney tissues displayed spe-
cific binding (data not shown), whereas the positive con-
trol (rat brain) showed clear specific binding to the fifth
cortical layer as previously reported [27].
The effects of relaxin deficiency on glomerular
protein and collagen
The glomeruli from the cortex of male RLX+/+ and
RLX−/− mice were isolated and analyzed for total pro-
tein and collagen content. Glomerular extracts from
RLX−/− mice (N = 8) yielded 42.4% (P < 0.01) more
protein, when compared to the same volume of sample,
analyzed from RLX+/+ mice (N = 6) (Fig. 4). A 42%
increase (P < 0.05) in hydroxyproline (collagen) expres-
sion was also measured from the glomeruli of RLX−/−
mice, compared to samples isolated from RLX+/+ an-
imals (Fig. 4). These findings demonstrated that the in-
creased glomerular protein measured in RLX−/− mice
was caused by the increased collagen (fibrosis) associated
with these cells, and confirmed the histologic findings of
diffuse increased glomerular matrix in relaxin-deficient
mice.
Functional consequences of relaxin deficiency
on the kidney
To determine whether the observed relaxin-deficient
induced changes in kidney structure and collagen were
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Fig. 2. Effects of relaxin deficiency on kidney
histology. Hematoxylin and eosin staining of
whole kidney sections from RLX+/+ (A) and
RLX−/− (B) mice were performed to com-
pare tissue size and structure. Kidney sections
from RLX−/− mice were larger in size than
those of RLX+/+ mice and contained thicker
cortices. Masson trichrome staining was used
to identify matrix (collagen) within the cor-
tical interstitium (C and D) and glomeruli
(E and F) of RLX+/+ and RLX−/− mice,
respectively. Quantitative analysis of stain-
ing indicated focal increases in interstitial
matrix (D) and diffuse increased glomerular
matrix (F) in RLX−/− mice. rH2-treatment
of RLX−/− mice resulted in a marked de-
creased in collagen staining within the inter-
stitial tubules (G) and glomeruli (H), as com-
pared to staining observed in untreated (D
and F) and vehicle alone–treated mouse kid-
ney sections.
associated with changes in kidney function of RLX−/−
mice, serum creatinine and total urine protein were deter-
mined in normal and relaxin-deficient mice. Serum crea-
tinine was modestly, but significantly (P < 0.05) increased
in 9- to 12-month-old RLX−/− mice (20.9 ± 1.0 mmol/L;
N = 7), compared with levels measured in RLX+/+ mice
(14.5 ± 3.2 mmol/L; N = 4) (Fig. 5). Total urinary protein
secretion from RLX−/− mice (17.4 ± 1.8 mg/24 hours;
N = 6) was also significantly (P < 0.05) increased, com-
pared with levels measured in RLX+/+ mice (11.2 ± 1.1
mg/24 hours; N = 6) (Fig. 5).
Reversal of renal fibrosis by recombinant human
relaxin treatment
The administration of rH2 to 12-month-old, male
RLX−/− mice (with established fibrosis) significantly de-
creased collagen expression in their kidneys (Fig. 6). Total
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Fig. 3. Reverse transcription-polymerase chain reaction (RT-PCR) of relaxin-1, relaxin-3, and LGR7 mRNA expression in immature (1 month)
and adult (9 months) RLX+/+ and RLX−/− mouse kidney tissues. Ethidium bromide-stained PCR products of mouse relaxin-1 (150 bp), relaxin-
3 (319 bp) and LGR7 (178bp) are shown, while glyceraldehyde-3-phosphate dehydrogenase (GAPDH) products (246 bp) were used as controls
for quality and equal loading of the cDNA. Samples consist of a molecular weight marker and duplicate samples from the 1-month-old cortex,
9-month-old cortex, 1-month-old medulla, and 9-month-old medulla of RLX+/+ and RLX−/− mice, respectively. cDNA from the pregnant mouse
ovary was used as a positive control for relaxin-1, while mouse brain and/or cortex were used as positive controls for relaxin-3 and LGR7. Water
replaced cDNA in negative control reactions for each PCR.
collagen content was inhibited in the cortex (by 62%, P <
0.05) and medulla (by 52%, P < 0.05) of RLX−/− mice,
resulting in a significant reduction of total kidney colla-
gen content (by 54%, P < 0.05), compared to levels mea-
sured in untreated relaxin-deficient mice. This resulted
in rH2 significantly decreasing (P < 0.05) total kidney
collagen concentration (collagen content as a percentage
of the dry weight tissue) by 12%, which represented ap-
proximately half of the increased collagen concentration,
measured in relaxin-deficient mice. However, the level
of collagen measured after rH2 treatment of RLX−/−
mice with established fibrosis, was still significantly higher
(P < 0.05) than those observed in kidney tissues of
RLX+/+ mice (Fig. 6). Histologic analysis of rH2-treated
kidneys from RLX−/− mice demonstrated a decrease in
tissue size and cortex size/thickness. Furthermore, rH2
treatment of RLX−/− mice decreased the level of col-
lagen staining associated with renal interstitial tubules
(Fig. 2G) and glomeruli (Fig. 2H). rH2 treatment (over
14 days) also caused a 35% to 40% decrease in serum cre-
atinine, compared with values obtained from the serum
of untreated RLX−/− mice. While this decrease in serum
creatinine was not statistically significant (P = 0.12),
these combined findings demonstrated that rH2 could be
used to successfully treat fibrosis associated with renal
disease.
DISCUSSION
In this study we have demonstrated for the first
time that male mice, lacking the relaxin-1 gene over a
lifetime developed an age-related progression of renal
fibrosis. Mature male relaxin-1–deficient mice had signif-
icantly increased kidney weight and size, in addition to
increased type I collagen deposition from 6 months of
age and older. The increased renal collagen of RLX−/−
mice led to increased renal collagen concentration by
12 months of age, and was associated with a marked thick-
ening of the cortex, glomerulosclerosis, and, to a lesser
extent, interstitial fibrosis. The increased fibrosis in RLX
−/− mice was also associated with a modest reduction
in kidney function. Treatment of relaxin-deficient mice
with recombinant human relaxin resulted in the reversal
of interstitial renal fibrosis, glomerulosclerosis, and cor-
tical thickening, when administered to established stages
of the disease. These findings confirm that relaxin is a
naturally occurring inhibitor of collagen turnover during
kidney development and implicate relaxin’s potential as
a therapeutic agent against diseases associated with or
caused by renal fibrosis.
Similar to the situation in the heart of relaxin-deficient
mice [20], the absence of relaxin was associated with in-
creased fibrosis in the aging kidney of male, but not fe-
male mice. In our previous studies we had also shown that
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Fig. 4. Effects of relaxin deficiency on to-
tal glomerular protein and collagen expres-
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and analyzed for differences in protein con-
tent and hydroxyproline (collagen) content.
Glomerular protein and collagen expression
in RLX−/− mouse samples was expressed
as a ratio of protein or collagen in RLX+/+
mouse tissues, respectively, which was always
expressed as 1. The numbers in parenthesis
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the lung of male mice developed a progressive and more
severe pulmonary fibrosis, as compared with that associ-
ated with female mice [19]. These combined findings sug-
gest that the progression of fibrosis is affected by gender
and that male RLX−/− mice represent more of a relaxin
“knockout” model, with no major compensatory factors
that appear to replace the loss of relaxin. This is consis-
tent with a meta-analytic report, which indicated that men
are associated with a more rapid rate of chronic renal dis-
ease and show a more rapid decline in renal function with
time than do women [29]. Female RLX−/− mice may
be protected to a certain extent by other female-specific
hormones or factors, such as estrogen, that may also
compensate for the absence of relaxin in aging knock-
out mice. This is consistent with previous studies demon-
strating that estradiol decreases collagen synthesis via
activation of a mitogen-activated protein (MAP) kinase
cascade [30] and reverses TGF-b1–induced cell apopto-
sis by a casein kinase-2–dependent mechanism [31] in
renal tissues and cells. The renal protective effects of
estrogen in females also include increased matrix met-
alloproteinase expression and reduced progression of
glomerulosclerosis [32]. Thus, it appears that some tis-
sues, such as the kidney, are more susceptible to influence
by gender-specific hormones/factors, which, in turn, may
prevent these tissues from the onset of fibrosis, caused by
relaxin deficiency.
The effects of relaxin on the kidney have become more
prevalent in recent times. In addition to being estab-
lished as a mediator of renal vasodilation, hyperfiltration,
and osmoregulatory changes associated with pregnancy
and when administered to nonpregnant mammals [33–
35], the peptide hormone has also recently been impli-
cated as a potential antifibrotic therapy for renal disease
[12, 13, 36]. Relaxin administration decreased intersti-
tial fibrosis and restored renal function, when applied
to a bromoethylamine-induced model of chronic papil-
lary necrosis [12]. Relaxin also restored renal function
when applied to models of renal mass reduction, pro-
duced by either infarction or surgical excision [13]. Our
data extend those observations by demonstrating that the
deletion of the relaxin gene, known to produce a peptide
that regulates collagen turnover, resulted in increased
long-term deposition and accumulation of collagen in the
aging kidney, that was similar to levels observed by short-
term renal injury [12, 13, 36]. While the whole kidney of
male RLX−/− was affected by fibrosis, the most promi-
nent changes in collagen expression were detected in the
cortex. Furthermore, the long-term progression of renal
fibrosis was consistent with decreased kidney function
in relaxin-deficient mice. Other studies have shown that
the normal glomerulus predominantly synthesizes type
IV collagen [37]. During renal injury or sclerosis, cells
change their phenotype, resulting in a marked increase
in fibronectin expression [36] and a moderate increase
in type I collagen [37] in the glomerulus. This is con-
sistent with the biochemical and morphometric findings
of our study, which demonstrated increased glomeru-
lar matrix (type I collagen) in the cortex of RLX−/−
mice. Thus, our findings demonstrate that relaxin is a
natural regulator of type I collagen in the developing
kidney.
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Fig. 6. Effects of rH2 treatment on the kidney of RLX-deficient mice. Total collagen content from the kidney cortex and medulla of 12-month-old
RLX+/+ mice, untreated RLX−/− mice, vehicle alone–treated RLX−/− mice, and 0.5 mg/kg/day rH2-treated RLX−/− mice is shown. Total
collagen content was derived from the sum of collagen content in the cortex and medulla of each tissue. Numbers in parenthesis represent number
of mice used from each group. ∗P < 0.05 whencompared with aged-matched untreated and vehicle-treated RLX−/− mouse collagen levels; #P <
0.05 when compared with total collagen from age-matched RLX+/+ mouse kidneys.
Importantly, relaxin treatment of RLX−/− mice with
established fibrosis resulted in a significantly decreased
(50% to 60%) total kidney collagen content, reflected by
decreased collagen deposition in the cortex and medulla.
As a result, relaxin treatment of RLX−/− mice decreased
the level of glomerulosclerosis and interstitial fibrosis,
observed in untreated animals and somewhat decreased
serum creatinine, consistent with its ability to increase
serum creatinine clearance and restore kidney function
over longer-term treatment periods in other models of fi-
brosis [12]. Although collagen levels in relaxin-treated
mice with established renal fibrosis were not fully re-
stored to that observed in normal RLX+/+ mice, these
findings confirm our previous studies on the lung of
RLX−/−mice [19]. They also confirm that relaxin is a
potent modulator of collagen overexpression, associated
with renal disease.
Consistent with our findings in the lung [19], we demon-
strated relaxin-1 and relaxin-3 mRNA expression in the
ageing male RLX+/+ and RLX−/− mouse kidney, while
there was no consistent evidence for the presence of
LGR7 gene transcripts. RT-PCR analysis confirmed that
relaxin-1 was only present in normal (RLX+/+) ani-
mals, while relaxin-3 was present in both immature and
adult RLX+/+ and RLX−/− mice. Preliminary stud-
ies of female RLX+/+ mouse tissues has also demon-
strated relaxin (33P-H2Rlx) binding in highly localized
regions within the kidney cortex and medulla (Dr. Tanya
Burazin, unpublished data), suggesting that relaxin of
renal origin may contribute to its protective effects in
the kidney. However, given the multiple abnormalities
in the phenotype of RLX−/− mice [16–20], it is also
plausible that other relaxins of systemic/extrarenal origin
may contribute to protective effects in the kidney. Since
changes associated with renal fibrosis were detected in
the presence of relaxin-3, it is unlikely that relaxin-3 has
a direct role in the regulation of collagen in the develop-
ing and adult kidney. We found no conclusive evidence
that LGR7 was present in the immature or adult kidney,
perhaps suggesting that LGR7 is expressed in specific cell
types or blood vessels, which may cause its expression
to be low or inconsistent when whole tissue is analyzed
and explain why relaxin receptor expression was not de-
tected by autoradiography. Alternatively, relaxin bind-
ing to receptors located elsewhere may in turn affect the
kidney. Preliminary data from our group suggests that
LGR7 is weakly expressed in late passage primary rat
mesangial cells (Dr. Ping Fu, unpublished data), which
is consistent with our initial hypothesis. Mesangial cells
are found in glomeruli, which, in turn, represent approx-
imately 7% of the total cortex. Therefore, the interac-
tion between mesangial cells and the collagen-producing
fibroblasts may represent one way in which relaxin ex-
erts its biological actions in the mouse kidney. Separate
data from our group have also demonstrated that relaxin
does not activate the LGR8 receptor in rodents (Dr. Ross
Bathgate, unpublished data), indicating that relaxin does
not mediate its effects in the mouse kidney, via LGR8.
Thus, further work is still required to quantitate LGR7
receptor numbers in RLX+/+ and RLX−/− mice, to de-
termine specific cell types that express relaxin receptors,
and to determine which effects of relaxin are mediated
through LGR7. The inability to detect relaxin binding
sites in the mouse kidney is in accord with previous find-
ings in a rat kidney model of fibrosis [12], even though
relaxin administration in that model reduced several
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markers for fibrosis and improved glomerular filtration
rate.
CONCLUSION
We have demonstrated that the removal of the relaxin-
1 gene from mice resulted in a build-up of collagen in
the kidney, which was associated with glomerulosclero-
sis, modest interstitial fibrosis and a modest but significant
decrease in renal function. Relaxin treatment of RLX−/−
mice with established renal fibrosis caused a significant
reduction in renal collagen deposition and somewhat re-
stored renal function in RLX−/− mice. Thus, relaxin may
provide an important means to regulate excessive colla-
gen deposition in kidney diseases associated with or char-
acterized by fibrosis.
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